Talking Medicines uses AI to turn medical congress discussions into pharma insights

Tern plc

Medical congresses generate large amounts of information about healthcare professionals’ (HCPs) treatment preferences, clinical priorities and views on pharmaceutical brands. However, extracting useful intelligence from these conversations remains a challenge for pharmaceutical companies and healthcare advertising agencies.

Discussions take place across conference sessions, webinars, social media and research presentations, often leaving valuable information spread across unstructured sources. Manual analysis can be slow, making it difficult to identify emerging trends, assess sentiment and respond to changes in clinical priorities.

Talking Medicines addresses this through its DrugVoice platform, which uses natural language processing, machine learning and large language models to analyse healthcare professional conversations and convert them into structured intelligence.

The platform can track changes in sentiment, identify recurring themes, assess responses to brand messaging and categorise healthcare professionals according to their behaviour, language and interests. This information can help pharmaceutical marketing teams understand treatment trends, identify unmet needs and develop more relevant communications.

The technology can also be applied throughout the medical congress process. Before an event, it can help identify areas of clinical interest and inform engagement strategies. During congresses, it can monitor changes in sentiment, identify influential voices and track reactions to messaging. Following an event, the analysis can be used to assess engagement, evaluate campaign performance and identify areas where communication may need to change.

For pharmaceutical companies and agencies, this provides a way to assess how messages are received by healthcare professionals and whether communications reflect their clinical priorities.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines uses AI to turn medical congress discussions into pharma insights

Talking Medicines uses AI to analyse healthcare professional conversations at medical congresses, turning discussions into structured insights that help...

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

Device Authority warns supermarket freezer cyberattack exposes connected device security risks

Device Authority warns that a cyberattack affecting around 700 French supermarkets exposes security weaknesses in connected industrial equipment and...

Breast cancer research highlights importance of patient intelligence in pharma

Talking Medicines highlights how AI-powered patient intelligence can help pharmaceutical companies understand breast cancer treatment experiences and identify unmet...

GLP-1 drugs linked to emerging research into mental health and addiction

Research into GLP-1 medicines is expanding beyond weight loss, with studies examining potential links to depression, cognitive function, alcohol...

Talking Medicines examines emerging links between GLP-1 drugs and mental health

Researchers are investigating the potential links between GLP-1 medicines and mental health, with early findings prompting further studies into...

Search